Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-vsgnj Total loading time: 0 Render date: 2024-07-16T09:19:33.887Z Has data issue: false hasContentIssue false

25 - Parkinson's Disease

from Part VII - Neurodegenerative Disorders

Published online by Cambridge University Press:  06 January 2010

By
David L. Sultzer  and
G. Webster Ross
Edited by
Daryl Fujii  and
Iqbal Ahmed
David L. Sultzer
Affiliation:
University of California at Los Angeles and VA Greater Los Angeles Healthcare System
G. Webster Ross
Affiliation:
VA Pacific Islands Healthcare System
Daryl Fujii
Affiliation:
University of Hawaii, Manoa
Iqbal Ahmed
Affiliation:
University of Hawaii, Manoa
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Spectrum of Psychotic Disorders
Neurobiology, Etiology and Pathogenesis
 , pp. 490 - 510
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aarsland, D., Larsen, J. P., Cummings, J. L., & Laake, K. (1999a). Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community based study. Archives of Neurology, 56, 595–601.Google Scholar
Aarsland, D., Larsen, J. P., Karlsen, K., Lim, N. G., & Tandberg, E. (1999b). Mental symptoms in Parkinson's disease are important contributors to caregiver distress. International Journal of Geriatric Psychiatry, 14, 866–74.Google Scholar
Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000). Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. Journal of the American Geriatrics Society, 48, 938–42.Google Scholar
Aarsland, D., Ballard, C., Larsen, J. P., & McKeith, I. (2001a). A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. International Journal of Geriatric Psychiatry, 16, 528–36.Google Scholar
Aarsland, D., Cummings, J. L., & Larsen, J. P. (2001b). Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 16, 184–91.Google Scholar
Aarsland, D., Laake, K., Larsen, J. P., & Janvin, C. (2002). Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. Journal of Neurology, Neurosurgery, and Psychiatry, 72, 708–12.Google Scholar
Aarsland, D., Hutchinson, M., & Larsen, J. P. (2003). Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 18, 937–41.Google Scholar
Arnulf, I., Bonnet, A. M., Damier, P., et al. (2000). Hallucinations, REM sleep, and Parkinson's disease. Neurology, 55, 281–8.Google Scholar
Ballard, C., Piggot, M., Johnson, M., et al. (2000). Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology, 48, 868–76.Google Scholar
Ballard, C. G., Jacoby, R., Del Ser, T., et al. (2004). Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. American Journal of Psychiatry, 161, 843–49.Google Scholar
Barnes, J. & David, A. S. (2001). Visual hallucinations in Parkinson's disease: A review and phenomenological survey. Journal of Neurology, Neurosurgery and Psychiatry, 70, 727–33.Google Scholar
Barnes, J., Boubert, L., Harris, J., Lee, A., & David, A. S. (2003). Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia, 41, 565–74.Google Scholar
Bodis-Wollner, I. (2003). Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism and Related Disorders, 9(Suppl 2), S83–9.Google Scholar
Breier, A., Sutton, V. K., Feldman, P. D., et al. (2002). Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biological Psychiatry, 52, 438–45.Google Scholar
Comella, C. L., Tanner, C. M., & Ristanovic, R. K. (1993). Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Annals of Neurology, 34, 710–14.Google Scholar
Court, J. A., Ballard, C. G., Piggot, M. A., et al. (2001). Visual hallucinations are associated with lower alpha-bungarotoxin binding in dementia with Lewy bodies. Pharmacology, Biochemistry, and Behavior, 70, 571–9.Google Scholar
Maindreville, A. D., Fenelon, G., & Mahieux, F. (2005). Hallucinations in Parkinson's disease: A follow-up study. Movement Disorders, 20, 212–17.Google Scholar
Del Tredici, K., Rub, U., Vos, R. A., Bohl, J. R., & Braak, H. (2002). Where does Parkinson disease pathology begin in the brain?Journal of Neuropathology and Experimental Neurology, 61, 413–26.Google Scholar
Diederich, N. J., Goetz, C. G., Raman, R., et al. (1998). Poor visual discrimination and visual hallucinations in Parkinson's disease. Clinical Neuropharmacology, 21, 289–95.Google Scholar
Diederich, N. J., Alesch, F., & Goetz, C. G. (2000). Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clinical Neuropharmacology, 23, 287–9.Google Scholar
Diederich, N. J., Poeri, V., & Goetz, C. G. (2003). Coping strategies for visual hallucinations in Parkinson's disease. Movement Disorders, 18, 831–2.Google Scholar
Diederich, N. J., Goetz, C. G., & Stebbins, G. T. (2005). Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. Movement Disorders, 20, 130–40.Google Scholar
Eichhorn, T., Brunt, E., & Oertel, W. H. (1996). Ondansetron treatment of L-dopa-induced psychosis. Neurology, 47, 1608–9.Google Scholar
Emre, M., Aarsland, D., Albanese, A., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. The New England Journal of Medicine, 351, 2509–18.Google Scholar
Fabbrini, G., Barbanti, P., Aurilia, C., et al. (2002). Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurological Science, 23, 41–3.Google Scholar
Factor, S. A., Feustel, P. J., Friedman, J. H., et al. (2003). Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology, 60, 1756–61.Google Scholar
Fall, P. A., Saleh, A., Fredrickson, M., Olsson, J. E., & Granerus, A. K. (2003). Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: A 9-year follow-up. Movement Disorders, 18, 1312–16.Google Scholar
Fenelon, G., Mahieux, F., Huon, R., & Ziegler, M. (2000). Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain, 123, 733–45.Google Scholar
Fernandez, H. H., Trieschmann, M. E., Burke, M. A., Jaques, C., & Friedman, J. H. (2003a). Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Movement Disorders, 18, 510–14.Google Scholar
Fernandez, H. H., Trieschmann, M. E., & Friedman, J. H. (2003b). Treatment of psychosis in Parkinson's disease: Safety considerations. Drug Safety, 26, 643–59.Google Scholar
Fernandez, H. H., Donnelly, E. M., & Friedman, J. H. (2004a). Long-term outcome of clozapine use for psychosis in parkinsonian patients. Movement Disorders, 19, 831–3.Google Scholar
Fernandez, H. H., Trieschmann, M. E., & Friedman, J. H. (2004b). Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience. Clinical Neuropharmacology, 27, 4–5.Google Scholar
Fernandez, H. H., Trieschmann, M. E., & Okun, M. S. (2005). Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease. Movement Disorders, 20, 104–5.Google Scholar
Food and Drug Administration, (2005). Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. FDA Public Health Advisory.
Friedman, J. H. (1991). The management of the levodopa psychosis. Clinical Neuropharmacology, 14, 283–95.Google Scholar
Friedman, J. H. & Fernandez, H. H. (2002). Atypical antipsychotics in Parkinson-sensitive populations. Journal of Geriatric Psychiatry and Neurology, 15, 156–70.Google Scholar
Goetz, C. G. (1999). Hallucinations in Parkinson's disease: The clinical syndrome. Advances in Neurology, 80, 419–23.Google Scholar
Goetz, C. G. & Stebbins, G. T. (1993). Risk factors for nursing home placement in advanced Parkinson's disease. Neurology, 43, 2227–9.Google Scholar
Goetz, C. G. & Stebbins, G. T. (1995). Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology, 45, 669–71.Google Scholar
Goetz, C. G., Tanner, C. M., & Klawans, H. L. (1982). Pharmacology of hallucinations induced by long-term drug therapy. American Journal of Psychiatry, 139, 494–7.Google Scholar
Goetz, C. G., Pappert, E. J., Blasucci, L. M., et al. (1998a). Intravenous levodopa in hallucinating Parkinson's disease patients: High dose challenge does not precipitate hallucinations. Neurology, 50, 515–17.Google Scholar
Goetz, C. G., Vogel, C., Tanner, C. M., & Stebbins, G. T. (1998b). Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology, 51, 811–14.Google Scholar
Goetz, C. G., Leurgans, S., Pappert, E. J., Raman, R., & Stemer, A. B. (2001). Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology, 57, 2078–82.Google Scholar
Goetz, C. G., Wuu, J., Curgian, L. M., & Leurgans, S. (2005). Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study. Neurology, 64, 81–6.Google Scholar
Harding, A. J., Broe, G. A., & Halliday, G. M. (2002). Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 125, 391–403.Google Scholar
Herrmann, N. & Lanctot, K. L. (2005). Do atypical antipsychotics cause stroke?CNS Drugs, 19, 91–103.Google Scholar
Jackson, J. A., Free, G. B. M., & Pike, H. V. (1923). The psychic manifestations in paralysis agitans. Archives of Neurology and Psychiatry, 10, 680–84.Google Scholar
Klein, C., Gordon, J., Pollak, L., & Rabey, J. M. (2003). Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clinical Neuropharmacology, 26, 8–11.Google Scholar
Koller, W. C., Weiner, W. J., Perlik, S., et al. (1981). Complications of chronic levodopa therapy: Long-term efficacy of drug holiday. Neurology, 31, 473–6.Google Scholar
Kulisevsky, J. & Roldan, E. (2004). Hallucinations and sleep disturbances in Parkinson's disease. Neurology, 63(Suppl. 3), S28–30.Google Scholar
Kuzuhara, S. (2001). Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. Journal of Neurology, 248(Suppl. 3), 28–31.Google Scholar
Leopold, N. A. (2000). Risperidone treatment of drug-related psychosis in patients with parkinsonism. Movement Disorders, 15, 301–4.Google Scholar
Lobotesis, K., Fenwick, J. D., Phipps, A., et al. (2001). Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology, 56, 643–9.Google Scholar
Lozano, A. M. & Mahant, N. (2004). Deep brain stimulation surgery for Parkinson's disease: Mechanisms and consequences. Parkinsonism and Related Disorders, 10(Suppl 1), S49–57.Google Scholar
Makoff, A. J., Graham, J. M., Arranz, M. J., et al. (2000). Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics, 10, 43–8.Google Scholar
Marras, C., McDermott, M. P., Rochon, P. A., et al. (2005). Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort. Neurology, 64, 87–93.Google Scholar
Marsh, L., Williams, J. R., Rocco, M., et al. (2004). Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology, 63, 293–300.Google Scholar
Menon, G. J., Rahman, I., Menon, S. J., & Dutton, G. N. (2003). Complex visual hallucinations in the visually impaired: The Charles Bonnet Syndrome. Surveys in Ophthalmology, 48, 58–72.Google Scholar
Morgante, L., Epifanio, A., Spina, E., et al. (2002). Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurological Sciences, 23S, 89–90.Google Scholar
Nagano-Saito, A., Washimi, Y., Arahata, Y., et al. (2004). Visual hallucination in Parkinson's disease with FDG PET. Movement Disorders, 19, 801–6.Google Scholar
Nisipeanu, P., Paleacu, D., & Korczyn, A. D. (1997). Infectious and postinfectious parkinsonism. In Movement Disorders: Neurologic Principles and Practice, ed. Watts, R. L. & Koller, W. C.. New York: McGraw-Hill.
Okada, K., Suyama, N., Oguro, H., Yamaguchi, S., & Kobayashi, S. (1999). Medication-induced hallucination and cerebral blood flow in Parkinson's disease. Journal of Neurology, 246, 365–8.Google Scholar
Pappert, E. J., Goetz, C. G., Niederman, F. G., Raman, R., & Leurgans, S. (1999). Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Movement Disorders, 14, 117–21.Google Scholar
Parkinson, J. [1817] (2002). An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223–36.Google Scholar
Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease: The Parkinson Study Group. New England Journal of Medicine, 340, 757–63.
Parkinson Study Group (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62, 241–8.
Perry, E. K., Marshall, E., Kerwin, J., et al. (1990). Evidence of a monoaminergic–cholinergic imbalance related to visual hallucinations in Lewy body dementia. Journal of Neurochemistry, 55, 1454–6.Google Scholar
Perry, E. K., McKeith, I., Thompson, P., et al. (1991). Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Annals of the New York Academy of Sciences, 640, 197–202.Google Scholar
Pollak, P., Tison, F., Rascol, O., et al. (2004). Clozapine in drug induced psychosis in Parkinson's disease: A randomized, placebo controlled study with open follow up. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 689–95.Google Scholar
Reading, P. J., Luce, A. K., & McKeith, I. G. (2001). Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: Preliminary finding from an open trial. Movement Disorders, 16, 1171–95.Google Scholar
Reddy, S., Factor, S. A., Molho, E. S., & Feustel, P. J. (2002). The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Movement Disorders, 17, 676–81.Google Scholar
Saint-Cyr, J. A., Taylor, A. E., & Lang, A. E. (1993). Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology, 43(Suppl. 6), S47–52.Google Scholar
Sanchez-Ramos, J., Ortoll, R., & Paulson, G. W. (1996). Visual hallucinations wih Parkinson's disease. Archives of Neurology, 53, 1265–8.Google Scholar
Schonfeldt-Lecuona, C. & Connemann, B. J. (2004). Aripiprazole and Parkinson's disease psychosis. American Journal of Psychiatry, 161, 373–4.Google Scholar
Schwab, R. S., Fabing, H. D., & Prichard, J. S. (1950). Psychiatric symptoms and syndromes in Parkinson's disease. American Journal of Psychiatry, 107, 901–7.Google Scholar
Sultzer, D. L., Brown, C., Mandelkern, M. A., et al. (2003). Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. American Journal of Psychiatry, 160, 341–9.Google Scholar
Tsuang, D. W., Dalan, A. M., Eugenio, C. J., et al. (2002). Familial dementia with Lewy bodies: A clinical and neuropathological study of 2 families. Archives of Neurology, 59, 1622–30.Google Scholar
Turner, T. H., Cookson, J. C., Wass, J. A. H., et al. (1984). Psychotic reactions during treatment of pituitary tumours with dopamine agonists. British Medical Journal, 280, 1101–3.Google Scholar
Wolters, E. C., Hurwitz, T. A., Mak, E., et al. (1990). Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology, 40, 832–4.Google Scholar
Zoldan, J., Friedberg, G., Livneh, M., & Melamed, E. (1995). Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology, 45, 1305–8.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Parkinson's Disease
  • Edited by Daryl Fujii, University of Hawaii, Manoa, Iqbal Ahmed, University of Hawaii, Manoa
  • Book: The Spectrum of Psychotic Disorders
  • Online publication: 06 January 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511543784.026
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Parkinson's Disease
  • Edited by Daryl Fujii, University of Hawaii, Manoa, Iqbal Ahmed, University of Hawaii, Manoa
  • Book: The Spectrum of Psychotic Disorders
  • Online publication: 06 January 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511543784.026
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Parkinson's Disease
  • Edited by Daryl Fujii, University of Hawaii, Manoa, Iqbal Ahmed, University of Hawaii, Manoa
  • Book: The Spectrum of Psychotic Disorders
  • Online publication: 06 January 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511543784.026
Available formats
×